Blueprint Medicines (NASDAQ:BPMC) has submitted a marketing application to the FDA seeking approval of RET inhibitor pralsetinib for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancers.
The filing was made under the agency’s Real-Time Oncology Review pilot program.
The company’s applications for RET-altered non-small cell lung cancer are currently under review in the U.S. and Europe.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.